Ocular Therapeutix, Inc. (OCUL)

Market Cap	1.03B
Revenue (ttm)	59.84M
Net Income (ttm)	-115.27M
Shares Out	154.89M
EPS (ttm)	-1.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,399,316
Open	6.65
Previous Close	6.66
Day's Range	6.51 - 6.79
52-Week Range	2.00 - 11.31
Beta	1.42
Analysts	Strong Buy
Price Target	15.83 (+136.98%)
Earnings Date	Aug 5, 2024

About OCUL

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 25, 2014
• Employees: 267
• Stock Exchange: NASDAQ
• Ticker Symbol: OCUL

Financial Performance

In 2023, OCUL's revenue was $58.44 million, an increase of 13.49% compared to the previous year's $51.49 million. Losses were -$80.74 million, 13.7% more than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for OCUL stock is "Strong Buy." The 12-month stock price forecast is $15.83, which is an increase of 136.98% from the latest price.

Price Target

$15.83

(136.98% upside)

Analyst Consensus: Strong Buy